Immunic (IMUX)
(Delayed Data from NSDQ)
$1.83 USD
-0.12 (-6.15%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $1.84 +0.01 (0.55%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth B Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.83 USD
-0.12 (-6.15%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $1.84 +0.01 (0.55%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth B Momentum C VGM
Zacks News
Immunic's (IMUX) Ulcerative Colitis Study Shows Positive Data
by Zacks Equity Research
Immunic (IMUX) reports positive results from the maintenance phase of the phase II study evaluating its lead candidate, vidofludimus calcium, to treat patients with ulcerative colitis.
Immunic (IMUX) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Immunic (IMUX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Immunic (IMUX) Falls as Phase II Ulcerative Colitis Study Fails
by Zacks Equity Research
Immunic's (IMUX) phase II CALDOSE-1 study, evaluating vidofludimus calcium in patients with moderate-to-severe ulcerative colitis, fails to meet primary endpoint. Stock down.
Is Immunic (IMUX) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Immunic (IMUX) and Owens & Minor (OMI) have performed compared to their sector so far this year.
Can Immunic (IMUX) Climb 357% to Reach the Level Wall Street Analysts Expect?
by Zacks Equity Research
The consensus price target hints at a 357.4% upside potential for Immunic (IMUX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
PTC Therapeutics to Commence Phase II/III Coronavirus Study in US
by Zacks Equity Research
PTC Therapeutics (PTCT) gets an FDA sanction to begin a phase II/III study on its DHODH inhibitor PTC299 as a potential treatment of COVID-19. The study will start in the United States shortly.
Why Immunic (IMUX) Stock Might be a Great Pick
by Zacks Equity Research
Immunic (IMUX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Immunic Gets FDA Allowance for Phase II Coronavirus Study
by Zacks Equity Research
Immunic (IMUX) gets a FDA allowance to begin a phase II study on its DHODH inhibitor IMU-838 for addressing COVID-19 in the United States. Top-line results on the same are awaited later this year.
High-Beta ETFs & Stocks to Tap the Soaring Stock Market
by Sweta Killa
While every corner of the market is enjoying this ascent, high-beta ETFs and stocks seem a perfect bet at present.
Corporate News for May 15, 2020
by Zacks Equity Research
Companies In The News Are: APDN, CSCO, IMUX, VRTU